Eupraxia Pharmaceuticals (EPRX) Competitors $3.90 +0.06 (+1.56%) As of 04/24/2025 03:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EPRX vs. DNA, GHRS, CRMD, RLAY, SAGE, CGEM, TYRA, VERV, AKBA, and MRVIShould you be buying Eupraxia Pharmaceuticals stock or one of its competitors? The main competitors of Eupraxia Pharmaceuticals include Ginkgo Bioworks (DNA), GH Research (GHRS), CorMedix (CRMD), Relay Therapeutics (RLAY), Sage Therapeutics (SAGE), Cullinan Therapeutics (CGEM), Tyra Biosciences (TYRA), Verve Therapeutics (VERV), Akebia Therapeutics (AKBA), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Eupraxia Pharmaceuticals vs. Ginkgo Bioworks GH Research CorMedix Relay Therapeutics Sage Therapeutics Cullinan Therapeutics Tyra Biosciences Verve Therapeutics Akebia Therapeutics Maravai LifeSciences Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Which has better earnings and valuation, EPRX or DNA? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Ginkgo Bioworks. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.07Ginkgo Bioworks$227.04M2.02-$892.87M-$10.68-0.74 Do insiders and institutionals hold more shares of EPRX or DNA? 78.6% of Ginkgo Bioworks shares are held by institutional investors. 9.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer EPRX or DNA? In the previous week, Ginkgo Bioworks had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for Ginkgo Bioworks and 3 mentions for Eupraxia Pharmaceuticals. Ginkgo Bioworks' average media sentiment score of 0.20 beat Eupraxia Pharmaceuticals' score of 0.00 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EPRX or DNA more profitable? Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Ginkgo Bioworks' return on equity of -58.54% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Ginkgo Bioworks -298.78%-58.54%-34.24% Does the MarketBeat Community prefer EPRX or DNA? Ginkgo Bioworks received 20 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesGinkgo BioworksOutperform Votes2446.15% Underperform Votes2853.85% Do analysts rate EPRX or DNA? Eupraxia Pharmaceuticals presently has a consensus target price of $10.50, indicating a potential upside of 172.73%. Ginkgo Bioworks has a consensus target price of $4.58, indicating a potential downside of 42.02%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Ginkgo Bioworks.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Ginkgo Bioworks 3 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.60 SummaryGinkgo Bioworks beats Eupraxia Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Eupraxia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EPRX vs. The Competition Export to ExcelMetricEupraxia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$138.02M$6.62B$5.42B$7.71BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-5.357.0522.1818.32Price / SalesN/A273.45397.31107.09Price / CashN/A65.6738.2034.62Price / Book128.336.506.834.25Net Income-$28.22M$142.50M$3.20B$247.51M7 Day Performance16.31%8.45%5.79%6.08%1 Month Performance5.62%-7.39%-5.53%-3.77%1 Year Performance31.85%-0.93%16.85%4.60% Eupraxia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EPRXEupraxia Pharmaceuticals1.7149 of 5 stars$3.85+0.3%$10.50+172.7%+31.8%$137.66MN/A-5.3529News CoverageHigh Trading VolumeDNAGinkgo Bioworks0.6224 of 5 stars$8.23-1.6%$4.58-44.4%N/A$475.42M$227.04M-0.63640GHRSGH Research3.1 of 5 stars$9.14+0.6%$30.86+237.6%-14.3%$473.72MN/A-11.5310Upcoming EarningsNews CoveragePositive NewsCRMDCorMedix2.8544 of 5 stars$7.18+0.6%$14.50+102.1%+71.7%$469.05M$43.47M-8.8830RLAYRelay Therapeutics2.8518 of 5 stars$2.75+6.8%$19.80+621.3%-49.8%$465.00M$10.01M-1.05330Upcoming EarningsInsider TradePositive NewsGap UpSAGESage Therapeutics3.7263 of 5 stars$7.48+1.0%$8.81+17.9%-44.4%$459.57M$41.24M-1.13690Gap UpCGEMCullinan Therapeutics2.2548 of 5 stars$7.81+0.9%$32.86+320.5%-56.9%$458.16MN/A-2.7630News CoveragePositive NewsTYRATyra Biosciences1.9934 of 5 stars$8.51+0.9%$30.83+262.3%-36.9%$450.20MN/A-5.2720Positive NewsVERVVerve Therapeutics2.8936 of 5 stars$5.06+22.7%$25.75+409.4%-12.2%$449.75M$32.33M-2.06110High Trading VolumeAKBAAkebia Therapeutics3.4834 of 5 stars$1.90+3.6%$6.50+243.0%+66.4%$447.66M$160.18M-8.24430Positive NewsMRVIMaravai LifeSciences4.3165 of 5 stars$1.73-2.5%$6.34+267.8%-73.0%$438.73M$259.19M-1.05610 Related Companies and Tools Related Companies Ginkgo Bioworks Competitors GH Research Competitors CorMedix Competitors Relay Therapeutics Competitors Sage Therapeutics Competitors Cullinan Therapeutics Competitors Tyra Biosciences Competitors Verve Therapeutics Competitors Akebia Therapeutics Competitors Maravai LifeSciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EPRX) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
